Lupin Limited (($IN:LUPIN)) announced an update on their ongoing clinical study. Study Overview: Lupin Limited is conducting a study titled ‘An ...

Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, 1 February 2019: Lupin is pleased to announce ...

Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla® Enables expanded patient access of rare disease medicine to treat myotonia symptoms in non-dystrophic myotonic ...

The study, published in Lancet Neurology, detailed the "head-to-head" trial implemented by the researchers to test two drugs, mexiletine and lamotrigine, on people with the condition. The trial, which ...